Published in Proc Natl Acad Sci U S A on August 25, 2014
CRISPR/Cas9-mediated viral interference in plants. Genome Biol (2015) 1.40
Nature Biotechnology's academic spinouts of 2016. Nat Biotechnol (2017) 1.38
Applications of CRISPR technologies in research and beyond. Nat Biotechnol (2016) 1.34
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Res (2015) 1.10
Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Sci Rep (2016) 0.98
Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res (2015) 0.97
Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol (2015) 0.92
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One (2015) 0.90
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology (2015) 0.90
Genome editing and the next generation of antiviral therapy. Hum Genet (2016) 0.88
Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol (2015) 0.87
The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. Discov Med (2015) 0.86
Inhibition of HSV-1 Replication by Gene Editing Strategy. Sci Rep (2016) 0.85
Highly Efficient CRISPR/Cas9-Mediated Cloning and Functional Characterization of Gastric Cancer-Derived Epstein-Barr Virus Strains. J Virol (2016) 0.81
In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining. Nucleic Acids Res (2016) 0.81
CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget (2016) 0.81
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog (2016) 0.80
A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci Rep (2017) 0.80
Epigenetics and Genetics of Viral Latency. Cell Host Microbe (2016) 0.79
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends Microbiol (2016) 0.79
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic. Methods (2015) 0.78
Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs. PLoS One (2015) 0.77
Engineering Plant Immunity: Using CRISPR/Cas9 to Generate Virus Resistance. Front Plant Sci (2016) 0.76
Transgenic Clustered Regularly Interspaced Short Palindromic Repeat/Cas9-Mediated Viral Gene Targeting for Antiviral Therapy of Bombyx mori Nucleopolyhedrovirus. J Virol (2017) 0.75
Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9. Sci Rep (2016) 0.75
Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLoS Pathog (2016) 0.75
HSV-1 tegument protein and the development of its genome editing technology. Virol J (2016) 0.75
CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget (2016) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell (2013) 24.00
CRISPR/Cas, the immune system of bacteria and archaea. Science (2010) 18.72
RNA-guided genetic silencing systems in bacteria and archaea. Nature (2012) 17.12
RNA-programmed genome editing in human cells. Elife (2013) 14.82
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell (2013) 13.43
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 13.37
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2013) 12.36
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet (2011) 9.88
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet (1964) 9.32
CRISPR-based adaptive immune systems. Curr Opin Microbiol (2011) 8.07
One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell (2013) 7.99
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol (2014) 6.85
Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis (2001) 6.35
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature (2014) 5.70
Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell (2013) 5.40
Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol (2014) 5.07
High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature (2014) 4.95
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol (2014) 4.41
Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst (1966) 4.19
Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol (2014) 4.16
Genome-wide single-cell analysis of recombination activity and de novo mutation rates in human sperm. Cell (2012) 3.52
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48
Sequence analysis of Raji Epstein-Barr virus DNA. Virology (1988) 1.95
Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol (1999) 1.80
Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res (2013) 1.48
Meganuclease-mediated Inhibition of HSV1 Infection in Cultured Cells. Mol Ther (2011) 1.11
In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease. Mol Ther Nucleic Acids (2014) 1.03
Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursors. Theor Biol Med Model (2011) 0.82